利妥昔单抗联合环磷酰胺治疗难治性肾病综合征患者的效果  

Effects of Rituximab combined with Cyclophosphamide in treatment of patients with refractory nephrotic syndrome

作　　者：周孝会 孙艳芬 ZHOU Xiaohui;SUN Yanfen(Department of Nephrology of Guiyang International Hospital,Guiyang 550000 Guizhou,China)

机构地区：[1]贵黔国际医院肾内科,贵州贵阳550000

出　　处：《中国民康医学》2025年第8期48-50,共3页Medical Journal of Chinese People’s Health

摘　　要：目的:观察利妥昔单抗联合环磷酰胺治疗难治性肾病综合征(RNS)患者的效果。方法:选取2023年1—12月该院收治的78例RNS患者进行前瞻性研究,按随机数字表法将其分为对照组和观察组各39例。对照组采用环磷酰胺治疗,观察组在对照组基础上联合利妥昔单抗治疗,比较两组临床疗效、治疗前后肾功能指标[24 h尿蛋白定量、血肌酐(Scr)、尿素氮(BUN)]水平和不良反应发生率。结果:观察组治疗总有效率为94.87%(37/39),高于对照组的76.92%(30/39),差异有统计学意义(P<0.05);治疗后,两组24 h尿蛋白定量、Scr、BUN水平均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:利妥昔单抗联合环磷酰胺治疗RNS患者可提高治疗总有效率,降低肾功能指标水平,效果优于单纯环磷酰胺治疗。Objective:To observe effects of Rituximab combined with Cyclophosphamide in treatment of patients with refractory nephrotic syndrome(RNS).Methods:A prospective study was conducted on 78 patients with RNS admitted to this hospital from January to December 2023.According to the random number table method,they were divided into control group and observation group,39 cases in each group.The control group was treated with Cyclophosphamide,while the observation group was treated with Rituximab on the basis of that of the control group.The clinical efficacies,the renal function indexes[24 h urinary protein quantification,serum creatinine(Scr),blood urea nitrogen(BUN)]levels before and after the treatment and the incidence of adverse reactions were compared between the two groups.Results:The total effective rate of the observation group was 94.87%(37/39),which was higher than 76.92%(30/39)of the control group,and the difference was statistically significant(P<0.05).After treatment,the levels of 24 h urinary protein quantification,Scr and BUN in the two groups were lower than those before the treatment,those in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Rituximab combined with Cyclophosphamide in the treatment of the RNS patients can improve the total effective rate of treatment and reduce the levels of renal function indexes.Moreover,it is superior to simple Cyclophosphamide treatment.

关 键 词：利妥昔单抗 环磷酰胺 难治性肾病综合征 肾功能 不良反应 

分 类 号：R692[医药卫生—泌尿科学]